Revenue segments as reported by the company.

Pharmacy revenues

Premiums

Fees and other revenues

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Pharmacy and other service costs

Medical costs and other benefit expenses

Selling, general and administrative expenses

Amortization of acquired intangible assets

Special items

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cigna

Express Scripts is a company that provides integrated pharmacy benefit management services including network-pharmacy claims processing; home delivery pharmacy services; specialty pharmacy benefit management, through its subsidiary Accredo; benefit-design consultation; drug-utilization review; formulary management; and medical and drug data analysis services to manage drug plans for health plans, self-insured employers and government agencies (both as administrator of employee benefits and public assistance programs). Express Scripts also offers pharmacy benefit management services for workers' compensation insurance programs. The program is accredited by URAC, the nation's largest accrediting body for pharmacy benefit management companies. The company processes pharmaceutical claims for members through a network of retail pharmacies. Its own automated pharmacies dispense long-term, chronic medications-like those for diabetes or heart disease-directly to members by home delivery.

Express Scripts

The Cigna Group is a global health company, which engages in the provision of global health services. It operates through the following segments: Evernorth Health Services, Cigna Healthcare, Other Operations, and Corporate. The Evernorth Health Services segment partners with health plans, employers, governmental organizations, and health care providers to solve challenges in the areas of pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty distribution, and care delivery and management solutions. The Cigna Healthcare segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. The Other Operations segment consists of the remainder of business operations, which includes certain ongoing businesses and exited businesses. The Corporate segment refers to net interest expense, certain litigation matters, expense associated with frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs, and eliminations for products and services sold between segments. The company was founded in 1792 and is headquartered in Bloomfield, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cigna posts strong Q4 earnings, eyes growth in specialized services

Cigna delivered strong financial results in Q4 2022, with robust revenue growth and operational performance across key business segments.
While facing challenges such as margin pressures and potential disenrollment, Cigna is well-positioned to capitalize on growth opportunities in 2023.
Strategic partnerships, customer-focused strategies, and financial discipline underscore Cigna's commitment to sustainable growth and shareholder value creation.
Investments in innovation, care coordination, and market expansion signal a proactive approach to navigating industry dynamics and driving future success.

Cigna reports robust Q1 earnings, eyes growth amid challenges

Cigna's Q1 2023 showcased strong financials, growth in key segments, and increased outlook.
Challenges include economic softening impact and margin expectations for the year.
Opportunities lie in customer relationships, innovation, and market-specific strategies.
Overall, Cigna remains confident in delivering on its financial and growth targets.

Cigna reports robust Q2 results, eyes growth through innovation

Cigna's Q2 2023 performance was strong, with revenue growth, customer expansion, and technological advancements driving positive outcomes.
While facing challenges like disenrollment and risk adjustment payables, Cigna is leveraging strengths in technology and cross-selling for growth.
Opportunities lie in partnerships like VillageMD, continued innovation, and strategic bidding strategies for future growth.
Overall, Cigna remains confident in delivering on adjusted EPS outlook for 2023 and 2024, with a focus on innovation and growth.

Cigna surpasses Q3 expectations, eyes $28 EPS in 2024

Cigna's Q3 performance exceeded expectations, driven by strong revenue and EPS growth across key business segments.
Strategic focus on innovation, affordability, and client partnerships positions Cigna well for future growth and value creation.
Challenges in margin expectations and enrollment declines require proactive management and strategic decision-making.
Opportunities lie in continued growth projections, strategic investments, and enhancing healthcare affordability and accessibility.

Cigna reports robust Q4 performance, eyes growth amid strategic changes

Cigna Group's Q4 2023 Earnings Call highlighted strong financial performance, leadership changes, and strategic decisions. Analyst inquiries focused on growth drivers, market outlook, and internal healthcare spend management. The outlook for 2024 includes expectations of solid adjusted EPS, revenue growth, and operating cash flow.

Cigna surpasses Q1 expectations, eyes growth through AI and biosimilars

Cigna's Q1 performance exceeded expectations, driven by strong revenue and EPS figures.
Despite challenges like noncash losses and disruptions, Cigna's strategic strengths in AI, biosimilars, and value-based care position it well for growth.
Opportunities in AI-driven healthcare solutions, biosimilar expansions, and strategic M&A offer avenues for future growth.
Cigna's focus on precision care solutions and client outcomes showcases its commitment to innovation and efficiency.

Cigna (CI) posts robust Q2 results, eyes biosimilar growth

Cigna (CI) reports strong Q2 financial results driven by Evernorth Health Services and Express Scripts' innovative programs.
Focus on affordability, access, and behavioral health services propels growth in U.S. employer business.
Challenges include navigating healthcare cost pressures and ensuring fair pricing negotiations.
Opportunities lie in biosimilar growth, sustainable revenue outlook, and strategic Medicare Advantage business sale.

Cigna reports robust Q3 earnings, eyes growth opportunities in 2025

Cigna's Q3 earnings call highlighted strong financial performance, strategic focus on shareholder value, and challenges in specialty drugs and cost trends. The company is optimistic about opportunities in 2025 and remains committed to delivering shareholder value through strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Initiative commits $9M over three years, with a first-year focus on housing stability Request for application now open for nonprofits prioritizing veteran mental health with programs and services directly connected to housing and homelessness challenges BLOOMFIELD, Conn. , Aug. 12, 2024  /PRNewswire/ -- The Cigna Group Foundation, the philanthropic arm of The Cigna Group (NYSE: CI), announced today a new grant program that will commit $9 million over three years to help improve the mental health and well-being of military veterans, with a first-year focus on housing stability among this specific population.

The Cigna Group Foundation Launches Grant Program To Improve Veteran Mental Health

Travelers

Automatic Data Processing

Chubb

Intuit

Progressive

Seasonal trading can be a benefit in stock selection. For an unknown reason, some equities perform well in some parts of the year and poorly in other parts of the year.

Stocks To Hold To Year End

Celestica

PayPal

Since July 16, volatility in the markets has increased. Stocks have entered correction territory, with the Nasdaq 100 down 13% from its peak.

The 3 Best Bargain Stocks to Buy in August 2024

BLOOMFIELD, Conn. , Aug. 5, 2024 /PRNewswire/ -- The Cigna Group Foundation, the philanthropic arm of The Cigna Group (NYSE: CI), today announced its first round of grant recipients for its new initiative to support youth mental health.

The Cigna Group Foundation Announces Grants to 22 Nonprofits to Help Address the Youth Mental Health Crisis

Cigna's (CI) Q2 results reflect new client wins in the Evernorth Health Services unit, partly offset by elevated pharmacy costs. It continues to expect adjusted EPS of at least $28.40 for 2024.

Cigna (CI) Q2 Earnings Top on Specialty Business Strength

The Cigna Group (NYSE:CI ) Q2 2024 Earnings Conference Call August 1, 2024 8:30 AM ET Company Participants Ralph Giacobbe - SVP of IR David Cordani - Chairman and CEO Brian Evanko - CFO, and President and CEO, Cigna Healthcare Eric Palmer - President and CEO, Evernorth Health Services Conference Call Participants Justin Lake - Wolfe Research Lisa Gill - JPMorgan A.J. Rice - UBS Andrew Mok - Barclays Scott Fidel - Stephens Ryan Langston - TD Cowen Josh Raskin - Nephron Research George Hill - Deutsche Bank Erin Wright - Morgan Stanley Stephen Baxter - Wells Fargo Dave Windley - Jefferies Jessica Tassan - Piper Sandler Lance Wilkes - Bernstein Operator Ladies and gentlemen, thank you for standing by for the Cigna Group Second Quarter 2024 Results Review.

The Cigna Group (CI) Q2 2024 Earnings Call Transcript

The headline numbers for Cigna (CI) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Cigna (CI) Reports Q2 Earnings: What Key Metrics Have to Say

Cigna (CI) came out with quarterly earnings of $6.72 per share, beating the Zacks Consensus Estimate of $6.42 per share. This compares to earnings of $6.13 per share a year ago.

Cigna (CI) Q2 Earnings and Revenues Beat Estimates

Cigna reported a second-quarter profit on Thursday that beat Wall Street estimates, helped by lower-than-expected medical costs and strength in its pharmacy benefit management unit.

Cigna beats profit estimates on lower-than-expected costs, pharmacy benefit boost

Total revenues for the second quarter 2024 increased 25% to $60.5 billion Shareholders' net income for the second quarter 2024 was $1.5 billion, or $5.45 per share Adjusted income from operations1 for the second quarter 2024 was $1.9 billion, or $6.72 per share 2024 outlook2 for adjusted income from operations1,2 is at least $28.40 per share BLOOMFIELD, Conn. , Aug. 1, 2024 /PRNewswire/ -- Global health company The Cigna Group (NYSE: CI) today reported strong second quarter 2024 results reflecting broad-based revenue and earnings growth across its businesses.

The Cigna Group Reports Strong Second Quarter 2024 Results

The Cigna Group reported $1.5 billion in second quarter profits as the diversified provider of medical insurance, pharmacy benefits and health services reaped new clients.

Cigna Profits Hit $1.5 Billion On Pharmacy And Health Services Growth

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Cigna (CI) is a Top-Ranked Growth Stock: Should You Buy?

Cigna's (CI) second-quarter earnings are expected to benefit from rising premiums and pharmacy revenues, partially offset by rising expenses.

Can Cigna (CI) Beat Q2 Earnings on Growing Pharmacy Revenues?

GE HealthCare Technologies Inc

HCA Healthcare

Intuitive Surgical

Eli Lilly

McKesson

Thermo Fisher Scientific

There are a whole host of reasons to invest in healthcare stocks over the long term. The United States has an aging population.

Healthy Profits: 7 Healthcare Stocks to Build a Lifetime of Wealth

Beyond analysts' top -and-bottom-line estimates for Cigna (CI), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.

Wall Street's Insights Into Key Metrics Ahead of Cigna (CI) Q2 Earnings

Cigna Group's medical memberships are focused on "services-only" commercial memberships. The fee-based rather than risk-based nature of these memberships makes Cigna more resilient to rising medical costs. The Evernorth segment should see high-single-digit growth for the foreseeable future, driven by Healthcare Services and specialty pharmacy Accredo.

Cigna Group: Services Focus Leads To Outperformance

Here is how Cigna (CI) and atai Life Sciences N.V. (ATAI) have performed compared to their sector so far this year.

Is Cigna Group (CI) Outperforming Other Medical Stocks This Year?

Cigna (CI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cigna (CI) Reports Next Week: Wall Street Expects Earnings Growth

Centene

UnitedHealth Group

Rising premiums, technological advancements and increased demand for Medicare plans are expected to drive the performances of the Zacks Medical-HMO industry players. UNH, CI and CNC are poised to benefit from encouraging industry prospects.

3 HMO Stocks Set to Thrive on a Varied Customer Base, Tech Investments

Commits $9M in Grants to Reduce Health Disparities beginning with the Houston, TX and Hartford, CT Communities BLOOMFIELD, Conn. , July 22, 2024 /PRNewswire/ -- As part of its ongoing commitment to community health and vitality, global health company The Cigna Group (NYSE: CI) today announced the creation of The Cigna Group Health Equity Impact Fund, a community program in which The Cigna Group Foundation will commit $9 million over three years to reduce key health barriers by specifically targeting health disparities most prevalent in local communities.

The Cigna Group Foundation Launches Its Health Equity Impact Fund

HubSpot

Spirit Airlines

Arvinas Inc

Flex Lng Ltd

Grifols, S.A.

CBRE Global Real Estate Income Fund

Inter & Co Inc

KKR Real Estate Finance Trust

Polestar Automotive Holding UK PLC

Rubrik Inc

We share 12 ideas published last week focused on stocks with less coverage on Seeking Alpha. Polestar Automotive Holding is seen as continuing to struggle with missed targets, high losses, and debt raises, warranting a sell. HubSpot faces volatility post-Google acquisition plans, while Grifols considers privatization amid debt concerns and shareholder issues.

Undercovered Dozen: Spirit Airlines, HubSpot, Cigna, First Quantum Minerals +

Tenet Healthcare

Universal Health Services

Expanding aging population and the increasing demand for affordable health products are likely to have boosted the performance of healthcare stocks in Q2. CI, UHS, HCA & THC are potential outperformers.

4 Healthcare Stocks Poised to Beat Q2 Earnings Estimates

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Cigna (CI) is a Strong Growth Stock

Dublin, July 15, 2024 (GLOBE NEWSWIRE) -- The "The Cigna Group - Digital transformation strategies" company profile has been added to ResearchAndMarkets.com's offering. This report provides insight into Cigna Group's tech activities, including its digital transformation strategies, its innovation programs, its technology initiatives, its estimated ICT budget, and its major ICT contracts. The Cigna Group (Cigna) is a health service company that offers integrated health plans and services such as medical, dental, disability, life and accident insurance and related products and services. Its major services include commercial medical health plans, government health plans, and specialty products and services in the areas of medical, behavioral, pharmacy management, dental and vision. Cigna offers these products to employers, organizations, individuals and other groups. Cigna offers its products through its sales offices in the domestic market and through distributors and licensees in foreign countries. Launched in July 2018, Behavioral Center of Excellence (BCoE), is as an innovation lab that enables Cigna teams to address challenges faced by both its customers and employees. The team consults business leaders across Cigna and its commercial business clients, to take a data-driven approach to innovation, to rapidly introduce new services to the market that meet the needs of health care consumers. Report Scope

The Cigna Group Digital Transformation Strategies Report 2024 - Accelerators, Incubators and Other Innovation Programs

CVS Health

The Federal Trade Commission is planning to sue three large U.S. health companies over their practices as middlemen who negotiate prices for medications such as insulin, a source familiar with the matter told CNBC. The suits are set to target the three biggest so-called pharmacy benefit managers, UnitedHealth Group's Optum Rx, CVS Health's Caremark and Cigna's Express Scripts, which are all owned by or connected to health insurers.

News for Cigna Stock (CI)